Chemical Nametisotumab vedotin-tftv
Dosage FormLyophilized powder (intravenous; 40 mg)
Drug ClassInhibitors
SystemFemale reproductive
CompanySeagen Inc.
Approval Year2021


  • For the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Last updated on 11/30/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tivdak (tisotumab vedotin-tftv) Prescribing Information2021Seagen Inc., Bothell, WA